WeVote
Log In

Bill

Bill

HB 1425

Requiring coverage of pharmacogenomic testing for psychotropic medications.

2025-2026 Regular Session Introduced by Liz Berry and 11 co-sponsors

HB 1425 requires Washington insurers to cover genetic testing that matches psychiatric patients to appropriate medications based on individual metabolism, aiming to improve treatment outcomes.

Public hearing in the House Committee on Health Care & Wellness at 1:30 PM.
0
WeVote Research Nonpartisan
Bill Summary · HB 1425

Legislative bill overview

HB 1425 mandates that health insurance plans cover pharmacogenomic testing for psychotropic medications—genetic tests that identify how individuals metabolize psychiatric drugs. The bill requires insurers to pay for these tests to help prescribers select medications and dosages tailored to a patient's genetic profile, potentially improving treatment outcomes and reducing adverse effects.

Why is this important

Psychotropic medications have highly variable effectiveness across individuals due to genetic differences in drug metabolism. Pharmacogenomic testing can reduce trial-and-error prescribing, potentially decreasing hospitalizations, emergency visits, and medication-related side effects. However, mandating coverage increases insurance costs, which may be passed to consumers through higher premiums.

Potential points of contention

  • Cost and insurance premiums: Mandatory coverage requirements increase insurer costs; unclear whether savings from better outcomes offset testing expenses and premium increases
  • Clinical evidence gaps: While promising, pharmacogenomic testing for psychiatry has less robust evidence than for some other medical conditions; some tests lack strong validation for all psychotropic drugs
  • Access equity concerns: Mandate may primarily benefit insured populations while leaving uninsured and underinsured patients behind, potentially widening mental health treatment disparities
  • Insurance market impacts: Insurers may object to mandates as reducing their pricing flexibility and competitiveness
  • Prescriber adoption barriers: Even with coverage, psychiatrists and primary care doctors may lack training or comfort implementing genetic testing results into practice

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.